Establishment and characterization of NCC-LGFMS1-C1: a novel patient-derived cell line of low-grade fibromyxoid sarcoma
Establishment and characterization of NCC-LGFMS1-C1: a novel patient-derived cell line of low-grade fibromyxoid sarcoma
复制标题
NCC-LGFMS1-C1 的建立和表征：一种新型患者来源的低级别纤维粘液样肉瘤细胞系
DOI：
10.1007/s13577-021-00612-1
复制
发表时间：
2021
期刊：
影响因子：
4.3
通讯作者：
Kondo Tadashi
中科院分区：
文献类型：
--
作者：
Yoshimatsu Yuki;Noguchi Rei;Sin Yooksil;Tsuchiya Ryuto;Ono Takuya;Sei Akane;Sugaya Jun;Iwata Shintaro;Yoshida Akihiko;Kawai Akira;Kondo Tadashi
Low-grade fibromyxoid sarcoma (LGFMS) is a rare soft-tissue sarcoma genetically characterized by the presence of theFUS-CREB3L2gene fusion. While LGFMS exhibits indolent features during its early stages, the rates of recurrence, metastasis, and death from the disease are high. Presently, the role ofFUS-CREB3L2gene fusions in the unique features of LGFMS is not clear, and there is no modality to improve the clinical outcomes of patients with LGFMS; thus, extensive studies on LGFMS are required. Patient-derived cancer cell lines are critical tools for cancer research. However, no cell line has been established for LGFMS. Here, we aimed to develop a novel cell line for LGFMS and successfully established it using surgically resected tumor tissues. The cells, named NCC-LGFMS1-C1, possessed the same fusion genes as their original tumor and visible copy number variations. The cells had a fibroblastic appearance, formed spheroids when they were seeded in a low-attachment dish, and exhibited constant growth and invasion. Additionally, we demonstrated the feasibility of high-throughput drug screening using these cells. In conclusion, the NCC-LGFMS1-C1 cell line is a useful tool for studying LGFMS.
